Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: Two case reports and literature review

Ryota Sakai, Hayato Nagasawa, Eiko Nishi, Ayumi Okuyama, Hirofumi Takei, Takahiko Kurasawa, Tsuneo Kondo, Koji Nishimura, Yuichiro Shirai, Tatsuya Ito, Hideto Kameda, Tsutomu Takeuchi, Koichi Amano

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. Recently, it has been reported that quite a few cases of refractory AOSD were successfully treated with tocilizumab (TCZ) and corticosteroids were withdrawn in some of these patients. We report two AOSD patients who were treated successfully with TCZ monotherapy; thus, avoiding corticosteroid treatment. Because both of the patients refused to take corticosteroids, we planned to treat them with 8 mg/kg of TCZ monotherapy at weeks 0, 2, 6 and subsequently every 4 weeks. The efficacy of TCZ was assessed by patients' clinical symptoms such as fever, arthralgia, skin eruptions, and laboratory markers such as serum levels of CRP, ferritin, and IL-6. We also reviewed 14 previous case reports including 30 cases who had been treated with TCZ for AOSD. Our patients responded rapidly and have been maintained in clinical remission without corticosteroid treatment. In the literature review, concomitant corticosteroid treatment described in 13 cases was successfully tapered in 7 and discontinued in 6 cases. TCZ monotherapy can be a candidate for the first-line therapy for some AOSD patients.

Original languageEnglish
Pages (from-to)569-574
Number of pages6
JournalClinical Rheumatology
Volume31
Issue number3
DOIs
Publication statusPublished - 2012 Mar

Fingerprint

Adult-Onset Still's Disease
Adrenal Cortex Hormones
Therapeutics
Arthralgia
Ferritins
tocilizumab
Interleukin-6
Fever
Biomarkers
Skin
Serum

Keywords

  • Adult-onset Still's disease
  • Interleukin-6
  • Monotherapy
  • Tocilizumab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Successful treatment of adult-onset Still's disease with tocilizumab monotherapy : Two case reports and literature review. / Sakai, Ryota; Nagasawa, Hayato; Nishi, Eiko; Okuyama, Ayumi; Takei, Hirofumi; Kurasawa, Takahiko; Kondo, Tsuneo; Nishimura, Koji; Shirai, Yuichiro; Ito, Tatsuya; Kameda, Hideto; Takeuchi, Tsutomu; Amano, Koichi.

In: Clinical Rheumatology, Vol. 31, No. 3, 03.2012, p. 569-574.

Research output: Contribution to journalArticle

Sakai, R, Nagasawa, H, Nishi, E, Okuyama, A, Takei, H, Kurasawa, T, Kondo, T, Nishimura, K, Shirai, Y, Ito, T, Kameda, H, Takeuchi, T & Amano, K 2012, 'Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: Two case reports and literature review', Clinical Rheumatology, vol. 31, no. 3, pp. 569-574. https://doi.org/10.1007/s10067-011-1917-9
Sakai, Ryota ; Nagasawa, Hayato ; Nishi, Eiko ; Okuyama, Ayumi ; Takei, Hirofumi ; Kurasawa, Takahiko ; Kondo, Tsuneo ; Nishimura, Koji ; Shirai, Yuichiro ; Ito, Tatsuya ; Kameda, Hideto ; Takeuchi, Tsutomu ; Amano, Koichi. / Successful treatment of adult-onset Still's disease with tocilizumab monotherapy : Two case reports and literature review. In: Clinical Rheumatology. 2012 ; Vol. 31, No. 3. pp. 569-574.
@article{c4c0c8b09f534f6eaed0cacbef10ed09,
title = "Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: Two case reports and literature review",
abstract = "Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. Recently, it has been reported that quite a few cases of refractory AOSD were successfully treated with tocilizumab (TCZ) and corticosteroids were withdrawn in some of these patients. We report two AOSD patients who were treated successfully with TCZ monotherapy; thus, avoiding corticosteroid treatment. Because both of the patients refused to take corticosteroids, we planned to treat them with 8 mg/kg of TCZ monotherapy at weeks 0, 2, 6 and subsequently every 4 weeks. The efficacy of TCZ was assessed by patients' clinical symptoms such as fever, arthralgia, skin eruptions, and laboratory markers such as serum levels of CRP, ferritin, and IL-6. We also reviewed 14 previous case reports including 30 cases who had been treated with TCZ for AOSD. Our patients responded rapidly and have been maintained in clinical remission without corticosteroid treatment. In the literature review, concomitant corticosteroid treatment described in 13 cases was successfully tapered in 7 and discontinued in 6 cases. TCZ monotherapy can be a candidate for the first-line therapy for some AOSD patients.",
keywords = "Adult-onset Still's disease, Interleukin-6, Monotherapy, Tocilizumab",
author = "Ryota Sakai and Hayato Nagasawa and Eiko Nishi and Ayumi Okuyama and Hirofumi Takei and Takahiko Kurasawa and Tsuneo Kondo and Koji Nishimura and Yuichiro Shirai and Tatsuya Ito and Hideto Kameda and Tsutomu Takeuchi and Koichi Amano",
year = "2012",
month = "3",
doi = "10.1007/s10067-011-1917-9",
language = "English",
volume = "31",
pages = "569--574",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Successful treatment of adult-onset Still's disease with tocilizumab monotherapy

T2 - Two case reports and literature review

AU - Sakai, Ryota

AU - Nagasawa, Hayato

AU - Nishi, Eiko

AU - Okuyama, Ayumi

AU - Takei, Hirofumi

AU - Kurasawa, Takahiko

AU - Kondo, Tsuneo

AU - Nishimura, Koji

AU - Shirai, Yuichiro

AU - Ito, Tatsuya

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

AU - Amano, Koichi

PY - 2012/3

Y1 - 2012/3

N2 - Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. Recently, it has been reported that quite a few cases of refractory AOSD were successfully treated with tocilizumab (TCZ) and corticosteroids were withdrawn in some of these patients. We report two AOSD patients who were treated successfully with TCZ monotherapy; thus, avoiding corticosteroid treatment. Because both of the patients refused to take corticosteroids, we planned to treat them with 8 mg/kg of TCZ monotherapy at weeks 0, 2, 6 and subsequently every 4 weeks. The efficacy of TCZ was assessed by patients' clinical symptoms such as fever, arthralgia, skin eruptions, and laboratory markers such as serum levels of CRP, ferritin, and IL-6. We also reviewed 14 previous case reports including 30 cases who had been treated with TCZ for AOSD. Our patients responded rapidly and have been maintained in clinical remission without corticosteroid treatment. In the literature review, concomitant corticosteroid treatment described in 13 cases was successfully tapered in 7 and discontinued in 6 cases. TCZ monotherapy can be a candidate for the first-line therapy for some AOSD patients.

AB - Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. Recently, it has been reported that quite a few cases of refractory AOSD were successfully treated with tocilizumab (TCZ) and corticosteroids were withdrawn in some of these patients. We report two AOSD patients who were treated successfully with TCZ monotherapy; thus, avoiding corticosteroid treatment. Because both of the patients refused to take corticosteroids, we planned to treat them with 8 mg/kg of TCZ monotherapy at weeks 0, 2, 6 and subsequently every 4 weeks. The efficacy of TCZ was assessed by patients' clinical symptoms such as fever, arthralgia, skin eruptions, and laboratory markers such as serum levels of CRP, ferritin, and IL-6. We also reviewed 14 previous case reports including 30 cases who had been treated with TCZ for AOSD. Our patients responded rapidly and have been maintained in clinical remission without corticosteroid treatment. In the literature review, concomitant corticosteroid treatment described in 13 cases was successfully tapered in 7 and discontinued in 6 cases. TCZ monotherapy can be a candidate for the first-line therapy for some AOSD patients.

KW - Adult-onset Still's disease

KW - Interleukin-6

KW - Monotherapy

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84859780892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859780892&partnerID=8YFLogxK

U2 - 10.1007/s10067-011-1917-9

DO - 10.1007/s10067-011-1917-9

M3 - Article

C2 - 22215118

AN - SCOPUS:84859780892

VL - 31

SP - 569

EP - 574

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 3

ER -